In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brompheniramine efficacy against cold symptoms shown in study, Whitehall tells FDA.

This article was originally published in The Tan Sheet

Executive Summary

BROMPHENIRAMINE STUDY "STRONGLY SUPPORTS" EFFICACY AGAINST COLDS, WHITEHALL told FDA in a May 7 submission on the antihistamine ingredient. The study, involving 225 subjects, was conducted by Jack Gwaltney, MD, University of Virginia, from November 1995 through August 1996. Results were submitted by Whitehall-Robins along with other data in response to the 1995 conclusion by a joint FDA advisory committee that there are insufficient data to establish the effectiveness of brompheniramine for the cold indication.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts